PTAB Won't Review AstraZeneca's Symbicort Inhaler Patent
The Patent Trial and Appeal Board has refused to hear Complex Innovations LLC's challenge to a patent protecting AstraZeneca AB's blockbuster asthma and COPD drug Symbicort, finding it wasn't anticipated by...To view the full article, register now.
Already a subscriber? Click here to view full article